Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
Quotes
All Instrument Types
- All Instrument Types
- Indices
- Equities
- ETFs
- Funds
- Commodities
- Currencies
- Crypto
- Bonds
- Certificates
Please try another search
🙌 It's Here: the Only Stock Screener You'll Ever Need Get Started
Novavax's COVID-19 Vaccine Wins FDA AdCom Blessing, Removing 'Major Overhang'
Published Jun 07, 2022 01:37PM ET
Updated Jun 07, 2022 05:47PM ET
© Reuters Novavax's COVID-19 Vaccine Wins FDA AdCom Blessing, Removing 'Major Overhang'
By Davit Kirakosyan
Novavax, Inc. (NASDAQ:NVAX) announced late Tuesday that the U.S. Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) recommends that the FDA grant Emergency Use Authorization (EUA) for its COVID-19 vaccine (NVX-CoV2373) for individuals aged 18 years and over.
"The advisory committee's positive recommendation acknowledges the strength of our data and the importance of a protein-based COVID-19 vaccine developed using an innovative approach to traditional vaccine technology," said CEO Stanley Erck. "In today's VRBPAC meeting, we heard the overwhelming support for our vaccine from physicians, healthcare organizations, and consumers who are eagerly anticipating a protein-based vaccine option. Consistent with submissions to regulatory authorities worldwide, we have already submitted an amendment with updated manufacturing information for the EUA to the FDA for review. We look forward to collaborating with the FDA as it makes its final decision."
The Novavax COVID-19 vaccine is not yet authorized for use in the U.S. If approved, it would join vaccines that have been on the market for over a year and a half from Pfizer (NYSE:PFE)/BioNTech SE (NASDAQ:BNTX), Moderna, Inc. (NASDAQ:MRNA), Johnson & Johnson (NYSE:JNJ), and others.
Cowen analyst Georgi Yordanov weighed in on Novavax following the news, saying they continue to expect EUA approval by the end of June/early July.
"It does appear that the risk of myocarditis will likely be noted on the label, similarly to the mRNA vaccines' labels, but we don't expect it to have a commercial impact," Yordanov commented. "This removes a major overhang for the stock."
Related Articles
Add Chart to Comment
Confirm Block
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
Report this comment
I feel that this comment is:
Comment flagged
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.